Today, we will study why Alector (ALEC) is a high risk/reward opportunity in 2020.
Company overview
Alector, Inc. is a clinical-stage biopharmaceutical company that is leveraging immune-neurology for treating neurodegenerative diseases. To date, pharmaceutical companies have to try to remove or prevent protein misfolding as a therapeutic principle for treating neurodegenerative diseases such as prion disease, ALS (amyotrophic lateral sclerosis), Alzheimer's disease, Parkinson's disease, and Polyglutamine disease. Alector is deploying principles from genetics, immunology, and neurology to target these neurodegenerative diseases. The company is using biomarker tests to assess patients best suited to benefit from